Drugs / 68Ga-NOTA-BBN-RGD
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT02747290 | Jul 2014 → Jul 2017 | prostate cancer | Peking Union Medical College Hospital | Unknown | No outcome recorded |
| Phase 11 trial | ||||||
| Phase 1 | NCT02749019 | Jul 2015 → Jul 2018 | breast cancer | Peking Union Medical College Hospital | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 68Ga-NOTA-BBN-RGD | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02747290 ↗ |
| Modality | Peptide | “a heterodimeric peptide BBN-RGD was synthesized from bombesin(7-14) and c(RGDyK) through a glutamate linker and then labeled with 68Ga” NCT02747290 ↗ |
| Route | Intravenous | “will be injected intravenously” NCT02747290 ↗ |